ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

The following paragraphs contain brief biographies of eachof the directors or in case of legal entities being director,their permanent representatives, with an indication of othermandates as member of administrative, management orsupervisory bodies in other companies during the previous fiveyears (with the exception of the subsidiaries of the Company):Gil Beyen, permanent representative of Gil Beyen BVBA: CBOand Managing Director (executive)Mr. Gil Beyen gained an MSc in bioengineering from theKatholieke Universiteit Leuven (Belgium) in 1984 and obtainedan MBA from the University of Chicago (U.S.) in 1990. Beforefounding TiGenix, he worked as a management consultant atArthur D. Little (ADL) in Brussels, where he was responsible fortheir healthcare and biotechnology practice. In this function,he has assisted a broad range of companies in the biomedicaland biotech industries through different stages of their growth.Before commencing his MBA, he worked three years as aresearch engineer in environmental biotechnology. Mr. Beyen isa manager of Axxis V&C BVBA, as well as member of the boardof BIO.be, and commissioner for the Flemish government onthe board of the Flemish Institute of Biotechnology (VIB).Eduardo Bravo: CEO and Managing Director (executive)Mr. Eduardo Bravo has more than 18 years experience in thepharmaceutical industry. His professional career includes severalsenior management positions at Sanofi-Aventis, includingVice President for Latin America, where he was in charge ofmore than 2000 employees and oversaw sales of more than€1 billion. At Sanofi-Aventis he also held positions such asMarketing and Sales Manager for Europe and General Managerfor Belgium. He also worked for 7 years in SmithKline Beechamin sales positions both nationally and internationally. Mr. Bravoholds a degree in Business Administration and an MBA (INSEAD,Fontainebleau, France). He is member of the board of Cellerix.Mr. Bravo was a member of the board of Genetrix S.L. fromFebruary 2006 until February 2008 and from Biobide S.L. fromDecember 2005 until January 2008. At present, Mr. Bravo isno longer a member of the administrative, managementor supervisory bodies or partner of any other company orpartnership other than Cellerix.Mounia Chaoui-Roulleau, permanent representative ofVentech S.A.: Director (non-executive)Ms. Mounia Chaoui-Roulleau studied Bioengineering at theEcole Centrale Paris and Molecular Biophysics at the Universityof Paris VI, where she earned her doctorate. Her extensive careerin the pharmaceuticals industry began at the Gustave RoussyInstitute and later continued as an analyst for Atlas Venture.She has been a consultant to Telesis and Altran Technologies.From 2001 to the present time, Ms. Chaoui-Roulleau has beena partner in Ventech. Ms. Chaoui-Roulleau is also a memberof the supervisory board of Inserm Transfert Initiative SA, andXytis Inc, and is a general partner at Ventech SA. Ventech SArepresented by Ms. Chaoui-Roulleau has also been a boardmember of Cellerix since 2007. Ms. Chaoui-Roulleau has alsoheld board positions at Biovex Ltd (sold for USD 1 Billion toAmgen), Eyegate Inc and Aptanomics SA in the past fiveyears, but is no longer on the board of these companies. Sheis also in charge of the following up of the following Ventechportfolio companies: Scynexis Inc and BMD SA.Koenraad Debackere: Director (non-executive)Dr. Koenraad Debackere is Professor of technology andinnovation management at the Katholieke Universiteit Leuvenand visiting Professor at various European business schools.Prof. Debackere is Managing Director of K.U.Leuven Research& Development and Chairman of the Gemma Frisius-FondsK.U.Leuven NV, the Venture Fund of the Katholieke UniversiteitLeuven. In February 2005, Dr. Debackere became GeneralManager of the Katholieke Universiteit Leuven. He also serves(or has served) on the board of 4AZA Bioscience NV, 4AZAHolding NV, AlgoNomics NV, Better3Fruit NV, Eyetronics NV, ISWLimits NV, IPCOS NV, IriDM NV, Living Stone Co-operatie CVBA,MetaLogic NV, MEAC NV, PharmaDM NV, Bico NV, QMedit NV,RNA-TEC NV, Synes NV, Leuven Innovatie VZW, Gemma Frisius-Fonds II NV, Leuven.Inc VZW, DCRF (Désiré Collen ResearchFoundation) VZW, eMedit NV, IWT, Netherlands GenomicsInitiative, Hoover Stichting VZW, Stichting Amici AlmaeMatris VZW, WeefWerf en Vlasnatie NV, Aquacare Belgium NV,Aquacare International NV, KBC Verzekeringen NV, GroepJoos NV, Vlerick Leuven Gent Management School NV.Willy Duron: Chairman and Independent DirectorMr. Willy Duron has been an independent board memberof TiGenix since February 2007. He started his career at ABBVerzekeringen in 1970, becoming a member of the executivecommittee in 1984. Willy Duron holds a MSc degree inmathematics from the University of Gent and a MSc degreein actuarial sciences from the Katholieke Universiteit Leuven.He is also member of the board of directors of Ravago NV,Vanbreda Risk & Benefits NV, Universitaire ZiekenhuizenLeuven, Universitair Centrum St Jozef Kortenberg andW&K, Agfa-Gevaert NV, Van Lanschot Bankiers NV and89 •